EphA2 and phosphoantigen-mediated selective killing of medulloblastoma by γδT cells preserves neuronal and stem cell integrity [0.03%]
EphA2和磷抗原介导的γδT细胞选择性杀伤髓母细胞瘤以保护神经元和干细胞的完整性
Lola Boutin,Mingzhi Liu,Julie Déchanet Merville et al.
Lola Boutin et al.
Medulloblastoma (MB) is a pediatric brain tumor that develops in the cerebellum, representing one of the most common malignant brain cancers in children. Standard treatments include surgery, chemotherapy, and radiation, but despite a 5-y su...
Surrogate markers of intestinal dysfunction associated with survival in advanced cancers [0.03%]
与晚期癌症患者生存率相关的肠功能障碍替代标志物
Roxanne Birebent,Damien Drubay,Carolina Alves Costa Silva et al.
Roxanne Birebent et al.
Deviations in the diversity and composition of the gut microbiota are called "gut dysbiosis". They have been linked to various chronic diseases including cancers and resistance to immunotherapy. Stool shotgun based-metagenomics informs on t...
Cellular and secretome profiling uncover immunological biomarkers in the prognosis of renal cell carcinoma patients [0.03%]
细胞和分泌组分析揭示了肾细胞癌患者预后中的免疫生物标志物
Le Tong,Veronika Kremer,Shi Yong Neo et al.
Le Tong et al.
Renal cell carcinoma (RCC) is recognized as an immunogenic tumor, yet tumor-infiltrating lymphocytes often exhibit diminished effector function. However, the mechanisms underlying reduced T and NK cell activity in RCC remain unclear. Here, ...
Enhancement of tumor immunogenicity by the introduction of non- proteinogenic amino acid azetidine-2-carboxylic acid [0.03%]
通过引入非蛋白氨基酸叠氮乙酸来增强肿瘤的免疫原性
Siyu Li,Shiqing Wang,Baorui Tian et al.
Siyu Li et al.
Despite the clinical success in the treatment of several types of cancers, the immune checkpoint inhibitors (ICIs) show limited response rates in cancers with low tumor mutational burden (TMB) and antigenicity. Here, we aim to enhance tumor...
Efficacy of anti-LAG3 and anti-PD-1 combination checkpoint inhibitor therapy against head and neck squamous cell carcinoma in a genetically engineered mouse model [0.03%]
基因工程小鼠模型中抗LAG3和抗PD-1联合检查点抑制剂疗法对头颈鳞癌的有效性研究
Felipe F Lamenza,Peyton Roth,Puja Upadhaya et al.
Felipe F Lamenza et al.
Head and neck squamous cell carcinoma (HNSCC) continues to be among the most common malignancies worldwide with limited treatment options for patients. Targeting the PD-1/PDL-1 axis is currently the only FDA approved immune checkpoint inhib...
A targeted MAVS fusion protein for controlled innate immune activation and antitumor therapy [0.03%]
用于控制固有免疫激活和抗肿瘤治疗的靶向MAVS融合蛋白
Muhan Wang,Zhijie Zhang,YouYou Yang et al.
Muhan Wang et al.
Targeted therapies leveraging the innate immune system are emerging as promising cancer treatments. The mitochondrial antiviral signaling protein (MAVS) plays a crucial role in initiating innate immune responses, but its clinical use is lim...
XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial [0.03%]
在一项Ib / II期临床试验中，XL888和pembrolizumab调节结直肠肿瘤的免疫环境
Maggie J Phillips,Olatunji B Alese,Natalie K Horvat et al.
Maggie J Phillips et al.
We conducted a phase Ib/II clinical trial to evaluate the safety, feasibility, and clinical activity of combining pembrolizumab (anti-PD-1) with XL888 (Hsp90 inhibitor) in patients with advanced colorectal cancer (CRC). We hypothesized that...
Clinical Trial
Oncoimmunology. 2025 Dec;14(1):2475620. DOI:10.1080/2162402X.2025.2475620 2025
MERTK inhibition improves therapeutic efficacy of immune checkpoint inhibitors in hepatocellular carcinoma [0.03%]
MERTK抑制可提高肝细胞癌免疫检查点抑制剂的治疗效果
Diana Llopiz,Leyre Silva,Marta Ruiz et al.
Diana Llopiz et al.
Immunotherapy with immune checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC) patients only achieves response rates of 25%-30%, indicating the necessity of new therapies for non-responder patients. Since myeloid-related suppressiv...
Humanized mouse models of KRAS-mutated colorectal and pancreatic cancers with HLA-class-I match for pre-clinical evaluation of cancer immunotherapies [0.03%]
用于评估癌症免疫疗法的KRAS突变型结直肠癌和胰腺癌人源化小鼠模型及I类HLA匹配
Maria E Davola,Olga Cormier,Madeleine Lepard et al.
Maria E Davola et al.
Cancer immunotherapy promises to treat challenging cancers including KRAS-mutated colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC). However, pre-clinical animal models that better mimic patient tumor and immune system int...
Mixed cryoglobulinemia decelerates hepatocellular carcinoma development in hepatitis C patients with SVR by downregulating regulatory B cells: a 12-year prospective cohort study [0.03%]
混合型冷球蛋白血症通过降低调节性B细胞的表达减缓丙肝患者获得病毒学应答后的肝细胞癌变：一项为期12年的前瞻性队列研究
Ming-Ling Chang,Jur-Shan Cheng,Wei-Ting Chen et al.
Ming-Ling Chang et al.
How mixed cryoglobulinemia (MC) affects cancer risk in chronic hepatitis C patients with sustained virologic response (SVR) remains unclear. In a 12-year prospective study, post-SVR MC was assessed every 3‒6 months. Among the 891 SVR patie...